Connection

Philip Hall to Treatment Outcome

This is a "connection" page, showing publications Philip Hall has written about Treatment Outcome.
Connection Strength

0.046
  1. Single-dose rasburicase 6 mg in the management of tumor lysis syndrome in adults. Pharmacotherapy. 2006 Jun; 26(6):806-12.
    View in: PubMed
    Score: 0.029
  2. Interstitial diphtheria toxin-epidermal growth factor fusion protein therapy produces regressions of subcutaneous human glioblastoma multiforme tumors in athymic nude mice. Clin Cancer Res. 2005 Jan 01; 11(1):329-34.
    View in: PubMed
    Score: 0.006
  3. A phase II study of DT fusion protein denileukin diftitox in patients with fludarabine-refractory chronic lymphocytic leukemia. Clin Cancer Res. 2003 Sep 01; 9(10 Pt 1):3555-61.
    View in: PubMed
    Score: 0.006
  4. Phase I trial of a novel diphtheria toxin/granulocyte macrophage colony-stimulating factor fusion protein (DT388GMCSF) for refractory or relapsed acute myeloid leukemia. Clin Cancer Res. 2002 May; 8(5):1004-13.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.